All In Biotech

Free tool

FAERS Monitor: Antivert

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 010721 or its brand name (Antivert, Meclizine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

2,847

Serious

1,381

49% of reports

Hospitalization

688

Death reported

179

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue337
  • dizziness295
  • nausea280
  • headache257
  • product dose omission issue235
  • pain221
  • diarrhoea214
  • fall190
  • dyspnoea180
  • drug ineffective175
  • pruritus148
  • off label use147
  • cough142
  • asthenia136
  • pain in extremity125

Reports by year received

View as table
YearReports
20043
20057
20065
20073
20081
201019
20118
201234
201322
201419
201522
201643
201731
201854
201956
2020134
2021215
2022404
2023378
2024449
2025578
2026362

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,312 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product dose omission issueSignal2355.95.2966
dizzinessSignal2954.43.9782
fallSignal1904.23.7471
coughSignal1423.73.2286
fatigueSignal3373.22.9526
pain in extremitySignal1253.12.6182
headacheSignal2573.02.7358
pruritusSignal1482.82.4179
astheniaSignal1362.72.3143
painSignal2212.72.3234
nauseaSignal2802.62.3288
diarrhoeaSignal2142.42.2188
dyspnoeaSignal1802.32.0142
off label use1471.21.17
drug ineffective1751.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.